{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T03:29:03Z","timestamp":1786418943824,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFA0915700"],"award-info":[{"award-number":["2023YFA0915700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"DOI":"10.1186\/s10020-026-01525-1","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T10:03:13Z","timestamp":1780740193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synthetic lethality between PBRM1 deficiency and PARP inhibitors: exploiting G2\/M checkpoint arrest in colorectal cancer"],"prefix":"10.1186","volume":"32","author":[{"given":"Mohd Tarequl","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhou","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"1525_CR1","doi-asserted-by":"publisher","first-page":"712765","DOI":"10.3389\/fonc.2021.712765","volume":"11","author":"A Aili","year":"2021","unstructured":"Aili A, Wen J, Xue L, Wang J. Mutational analysis of PBRM1 and significance of PBRM1 mutation in anti-PD-1 immunotherapy of clear cell renal cell carcinoma. Front Oncol. 2021;11:712765.","journal-title":"Front Oncol"},{"issue":"6","key":"1525_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/jmedgenet-2014-102912","volume":"52","author":"PR Benusiglio","year":"2015","unstructured":"Benusiglio PR, Couv\u00e9 S, Gilbert-Dussardier B, Deveaux S, Le Jeune H, Da Costa M, Fromont G, Memeteau F, Yacoub M, Coupier I. A germline mutation in PBRM1 predisposes to renal cell carcinoma. J Med Genet. 2015;52(6):426\u201330.","journal-title":"J Med Genet"},{"issue":"1","key":"1525_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cancers12010016","volume":"12","author":"L Carril-Ajuria","year":"2019","unstructured":"Carril-Ajuria L, Santos M, Rold\u00e1n-Romero JM, Rodriguez-Antona C, de Velasco G. Prognostic and predictive value of PBRM1 in clear cell renal cell carcinoma. Cancers. 2019;12(1):16.","journal-title":"Cancers"},{"key":"1525_CR4","doi-asserted-by":"crossref","unstructured":"Carril-Ajuria L, Santos M, Rold\u00e1n-Romero JM, Rodriguez-Antona C, de Velasco G. Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma. Cancers. 2020;12(1):16. https:\/\/www.mdpi.com\/2072-6694\/12\/1\/16.","DOI":"10.3390\/cancers12010016"},{"issue":"11","key":"1525_CR5","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1158\/0008-5472.CAN-21-0628","volume":"81","author":"RM Chabanon","year":"2021","unstructured":"Chabanon RM, Morel D, Eychenne T, Colmet-Daage L, Bajrami I, Dorvault N, Garrido M, Meisenberg C, Lamb A, Ngo C. PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer. Cancer Res. 2021;81(11):2888\u2013902.","journal-title":"Cancer Res"},{"issue":"5","key":"1525_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.molcel.2022.12.031","volume":"83","author":"K Concannon","year":"2023","unstructured":"Concannon K, Morris BB, Gay CM, Byers LA. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Mol Cell. 2023;83(5):660\u201380.","journal-title":"Mol Cell"},{"key":"1525_CR8","doi-asserted-by":"publisher","first-page":"1066347","DOI":"10.3389\/fgene.2022.1066347","volume":"13","author":"J Dai","year":"2023","unstructured":"Dai J, Cui Y, Liang X, Xu J, Li J, Chen Y, Zhang E, Guo R. PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. Front Genet. 2023;13:1066347.","journal-title":"Front Genet"},{"issue":"20","key":"1525_CR9","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1080\/15384101.2015.1085137","volume":"14","author":"I Dale Rein","year":"2015","unstructured":"Dale Rein I, Solberg Landsverk K, Micci F, Patzke S, Stokke T. Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation. Cell Cycle. 2015;14(20):3248\u201360.","journal-title":"Cell Cycle"},{"issue":"1","key":"1525_CR10","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12885-021-08188-7","volume":"21","author":"Ce de Gloria","year":"2021","unstructured":"de Gloria Ce, Jesu\u00edno H, Nogueira L, Grudzinski B, da Costa Ghignatti P, Guecheva PV, Leguisamo TNM, N., Saffi J. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells. BMC Cancer. 2021;21(1):448.","journal-title":"BMC Cancer"},{"key":"1525_CR11","doi-asserted-by":"crossref","unstructured":"Espana-Agusti J, Warren A, Chew SK, Adams DJ, Matakidou A. Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis. Nat Commun. 2017;8(1):2026.","DOI":"10.1038\/s41467-017-02245-1"},{"issue":"6","key":"1525_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1158\/1541-7786.MCR-17-0607","volume":"16","author":"P Fang","year":"2018","unstructured":"Fang P, Madden JA, Neums L, Moulder RK, Forrest ML, Chien J. Olaparib-induced adaptive response is disrupted by FOXM1 targeting that enhances sensitivity to PARP inhibition. Mol Cancer Res. 2018;16(6):961\u201373.","journal-title":"Mol Cancer Res"},{"issue":"13\u201314","key":"1525_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1101\/gad.349249.121","volume":"36","author":"H Feng","year":"2022","unstructured":"Feng H, Lane KA, Roumeliotis TI, Jeggo PA, Somaiah N, Choudhary JS, Downs JA. PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2\/M checkpoint maintenance. Genes Dev. 2022;36(13\u201314):790\u2013806.","journal-title":"Genes Dev"},{"issue":"5","key":"1525_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41389-021-00329-8","volume":"10","author":"M Fernando","year":"2021","unstructured":"Fernando M, Duijf PH, Proctor M, Stevenson AJ, Ehmann A, Vora S, Skalamera D, Adams M, Gabrielli B. Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours. Oncogenesis. 2021;10(5):41.","journal-title":"Oncogenesis"},{"key":"1525_CR15","doi-asserted-by":"publisher","first-page":"1343004","DOI":"10.3389\/fonc.2024.1343004","volume":"14","author":"N Fultang","year":"2024","unstructured":"Fultang N, Schwab AM, McAneny-Droz S, Grego A, Rodgers S, Torres BV, Heiser D, Scherle P, Bhagwat N. PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer. Front Oncol. 2024;14:1343004.","journal-title":"Front Oncol"},{"issue":"6","key":"1525_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3892\/ol.2021.13096","volume":"22","author":"S Gad","year":"2021","unstructured":"Gad S, Le Teuff G, Nguyen B, Verkarre V, Duchatelle V, Molinie V, Posseme K, Grandon B, Da Costa M, Job B. Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway. Oncol Lett. 2021;22(6):835.","journal-title":"Oncol Lett"},{"key":"1525_CR17","doi-asserted-by":"publisher","first-page":"870229","DOI":"10.3389\/fonc.2022.870229","volume":"12","author":"D Gu","year":"2022","unstructured":"Gu D, Dong K, Jiang A, Jiang S, Fu Z, Bao Y, Huang F, Yang C, Wang L. PBRM1 deficiency sensitizes renal cancer cells to DNMT inhibitor 5-fluoro-2\u2019-deoxycytidine. Front Oncol. 2022;12:870229.","journal-title":"Front Oncol"},{"issue":"15","key":"1525_CR18","doi-asserted-by":"publisher","first-page":"e2322563121","DOI":"10.1073\/pnas.2322563121","volume":"121","author":"T He","year":"2024","unstructured":"He T, Cheng C, Qiao Y, Cho H, Young E, Mannan R, Mahapatra S, Miner SJ, Zheng Y, Kim N. Development of an orally bioavailable mSWI\/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. Proc Natl Acad Sci. 2024;121(15):e2322563121.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"1525_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5(4):387\u201393.","journal-title":"Mol Oncol"},{"issue":"9","key":"1525_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG Kaelin Jr","year":"2005","unstructured":"Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689\u201398.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1525_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2022.8428","volume":"48","author":"Y Lai","year":"2022","unstructured":"Lai Y, Li Z, Lu Z, Zheng H, Chen C, Liu C, Yang Y, Tang F, He Z. Roles of DNA damage repair and precise targeted therapy in renal cancer. Oncol Rep. 2022;48(6):1\u201312.","journal-title":"Oncol Rep"},{"key":"1525_CR24","doi-asserted-by":"publisher","unstructured":"Li X, Zou L. BRCAness, DNA gaps, and gain and loss of PARP inhibitor\u2013induced synthetic lethality. J Clin Invest. 2024;134(14). https:\/\/doi.org\/10.1172\/JCI181062.","DOI":"10.1172\/JCI181062"},{"issue":"1","key":"1525_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13059-015-0685-2","volume":"16","author":"Z Li","year":"2015","unstructured":"Li Z, Dai H, Martos SN, Xu B, Gao Y, Li T, Zhu G, Schones DE, Wang Z. Distinct roles of DNMT1-dependent and DNMT1-independent methylation patterns in the genome of mouse embryonic stem cells. Genome Biol. 2015;16(1):115.","journal-title":"Genome Biol"},{"issue":"18","key":"1525_CR22","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1182\/bloodadvances.2022009455","volume":"7","author":"BE Li","year":"2023","unstructured":"Li BE, Li GY, Cai W, Zhu Q, Seruggia D, Fujiwara Y, Vakoc CR, Orkin SH. In vivo CRISPR\/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice. Blood Adv. 2023;7(18):5281\u201393.","journal-title":"Blood Adv"},{"key":"1525_CR23","doi-asserted-by":"crossref","unstructured":"Li J, Zhang L, Shang Y, Liu J, Zhao H. Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance. Clin Translational Med. 2026;16(1):e70586.","DOI":"10.1002\/ctm2.70586"},{"issue":"5","key":"1525_CR26","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2018.09.032","volume":"175","author":"N Mashtalir","year":"2018","unstructured":"Mashtalir N, D\u2019Avino AR, Michel BC, Luo J, Pan J, Otto JE, Zullow HJ, McKenzie ZM, Kubiak RL, Pierre RS. Modular organization and assembly of SWI\/SNF family chromatin remodeling complexes. Cell. 2018;175(5):1272\u201388. e1220.","journal-title":"Cell"},{"issue":"2","key":"1525_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/annonc\/mdw552","volume":"28","author":"D Morel","year":"2017","unstructured":"Morel D, Almouzni G, Soria J-C, Postel-Vinay S. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. Ann Oncol. 2017;28(2):254\u201369.","journal-title":"Ann Oncol"},{"issue":"12","key":"1525_CR28","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.celrep.2017.02.074","volume":"18","author":"AM Nargund","year":"2017","unstructured":"Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S. The SWI\/SNF protein PBRM1 restrains VHL-loss-driven clear cell renal cell carcinoma. Cell Rep. 2017;18(12):2893\u2013906.","journal-title":"Cell Rep"},{"issue":"2","key":"1525_CR29","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1002\/ijc.27822","volume":"132","author":"R Paw\u0142owski","year":"2013","unstructured":"Paw\u0142owski R, M\u00fchl SM, Sulser T, Krek W, Moch H, Schraml P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer. 2013;132(2):E11\u20137.","journal-title":"Int J Cancer"},{"issue":"10","key":"1525_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7331","key":"1525_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature09639","volume":"469","author":"I Varela","year":"2011","unstructured":"Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin M-L, Teague J. Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469(7331):539\u201342.","journal-title":"Nature"},{"issue":"8","key":"1525_CR32","doi-asserted-by":"publisher","first-page":"e0180862","DOI":"10.1371\/journal.pone.0180862","volume":"12","author":"H Wang","year":"2017","unstructured":"Wang H, Qu Y, Dai B, Zhu Y, Shi G, Zhu Y, Shen Y, Zhang H, Ye D. PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine\/chemokine receptor interaction pathway. PLoS ONE. 2017;12(8):e0180862.","journal-title":"PLoS ONE"},{"key":"1525_CR33","doi-asserted-by":"crossref","unstructured":"Wu L, Deng Y, Lei Z, Wang Y, Huang S. Synthetic Lethality-Based Targets and Their Exploration in Tumour Combination Strategies. J Cell Mol Med. 2025;29(16):e70756.","DOI":"10.1111\/jcmm.70756"},{"issue":"5","key":"1525_CR34","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41556-023-01122-y","volume":"25","author":"X Yao","year":"2023","unstructured":"Yao X, Hong JH, Nargund AM, Ng MSW, Heng HL, Li Z, Guan P, Sugiura M, Chu PL, Wang LC. PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-\u03baB pathway in clear cell renal cell carcinoma. Nat Cell Biol. 2023;25(5):765\u201377.","journal-title":"Nat Cell Biol"},{"key":"1525_CR35","doi-asserted-by":"publisher","first-page":"e2500035","DOI":"10.1200\/PO-25-00035","volume":"9","author":"L Zhang","year":"2025","unstructured":"Zhang L, Wang Y, Qiao R, Zhang Y, Qiang H, Du H, Wen F, Liu M, Zhou Y, Nie W. Synthetic lethal co-mutations in DNA damage response pathways predict response to immunotherapy in pan-cancer. JCO Precision Oncol. 2025;9:e2500035.","journal-title":"JCO Precision Oncol"},{"issue":"1","key":"1525_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41698-023-00409-5","volume":"7","author":"K Zimmer","year":"2023","unstructured":"Zimmer K, Kocher F, Untergasser G, Kircher B, Amann A, Baca Y, Xiu J, Korn WM, Berger MD, Lenz H-J. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system. NPJ precision Oncol. 2023;7(1):64.","journal-title":"NPJ precision Oncol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01525-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01525-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01525-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:50:40Z","timestamp":1786416640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01525-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01525-1","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. The study does not include identifiable individual data.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"125"}}